Abstract:Background: One of the most common cancers worldwide is hepatocellular carcinoma (HCC). Studies have shown that Hepatitis B virus (HBV) X gene (HBx) mutations play a potentially important oncogenic role in the pathogenesis of this disease. However, the molecular mechanisms underlying the malignant transformation of liver cells following HBV infection are poorly understood. We previously identified a novel deletion mutation in HBx (HBx-d382) that is capable of transforming hepatocytes and increasing their tumorigenic capacity. As part of the afore-mentioned study, we also identified reverse transcriptase enzyme (rt)/s* double mutants in nucleoside analogue (NA)-resistant patients. This current study was conducted to determine if HBx-d382 and rt/s* mutations co-exist in HCC patients. The study also aimed to identify the role of these mutations in HCC. Methods: DNA from serum samples obtained from 152 NA-resistant patients with chronic hepatitis B (CHB) and 33 patients with HCC were sequenced to identify samples harboring both the HBx-d382 mutation and rt/s* double mutations. As part of this study, we also generated lentivirus constructs carrying different HBV mutations including rtA181T/sW172*, rtM204I/sW196*, HBx-d382, rtA181T/sW172*/HBx-d382 and rtM204I/sW196*/HBx-d382. The recombinant viral constructs were used to infect a human hepatocyte cell line (LO2). The LO2 cell line was used to evaluate the effect of the mutations on apoptosis, cellular proliferation and the rate of colony formation in the LO2 cells harboring different mutations. Results: We identified rt/s*/HBx-d382 mutations in both HBV-related HCC and NA-resistant CHB clinical samples and observed that the rate of occurrence of rt/s*/HBx-d382 mutations in HBV-related HCC is relatively high. The results of this study revealed that the rtA181T/sW172* and rtM204I/sW196* double mutants exhibited enhanced proliferation, reduced apoptosis and an increased rate of colony formation in LO2 cells. Expression of p53 and CyclinD1 were increased and the level of p21 was decreased in the rtA181T/sW172* and rtM204I/sW196* expressing LO2 cells. More importantly, rt/s* double mutations combined with the HBx-d382 mutation resulted in more severe phenotypes compared with rt/s* double mutation alone in LO2 cell lines. Conclusions: Our data suggest that rt/s*/HBx-d382 triple mutants play a crucial role in HBV-mediated HCC formation.

Hepatitis B Virus Core Promoter A1762T/G1764A (TA)/T1753A/T1768A Mutations Contribute to Hepatocarcinogenesis by Deregulating Skp2 and P53

P53 Promotes Proteasome-Dependent Degradation of Oncogenic Protein HBx by Transcription of MDM2.

Sequential Accumulation of the Mutations in Core Promoter of Hepatitis B Virus is Associated with the Development of Hepatocellular Carcinoma in Qidong, China.

HBV Rewires Liver Cancer Signaling by Altering PP2A Complexes

Hepatitis B Virus X Protein Inhibits P53 Sequence-Specific DNA Binding, Transcriptional Activity, and Association with Transcription Factor ERCC3.

HBx Deletion-Mutant Combined with the Reverse Transcriptase Enzyme/s* Mutation is Involved in HBV Mediated Liver Cell Proliferation and Apoptosis

Hepatitis B Virus X Protein Inhibits P53-Mediated Upregulation of Mitofusin-2 in Hepatocellular Carcinoma Cells

Synergistic Effect of MC-LR and C-Terminal Truncated HBx on HepG2 Cells and Their Effects on PP2A Mediated Downstream Target of MAPK Signaling Pathway

The Effects and Underlying Mechanisms of Hepatitis B Virus X Gene Mutants on the Development of Hepatocellular Carcinoma

Interaction of mutant hepatitis B X protein with p53 tumor suppressor protein affects both transcription and cell survival

Mutations in the Core Promoter of Hepatitis B Virus and Viral Genotype Are Correlated with Hepatocellular Carcinoma

Hepatitis B Virus X Protein Stimulates Proliferation, Wound Closure and Inhibits Apoptosis of HuH-7 Cells via CDC42

Hepatitis B Virus X Protein Amplifies TGF-β Promotion on HCC Motility Through Down-Regulating PPM1a

Hepatitis B Virus X Protein in the Proliferation of Hepatocellular Carcinoma Cells

Hepatitis B virus X (HBx) induces tumorigenicity of hepatic progenitor cells in 3,5-diethoxycarbonyl-1,4-dihydrocollidine-treated HBx transgenic mice.

Truncated Hbx-Dependent Silencing of Gas2 Promotes Hepatocarcinogenesis Through Deregulation of Cell Cycle, Senescence and P53-Mediated Apoptosis

Naturally occurring basal core promoter A1762T/G1764A dual mutations increase the risk of HBV-related hepatocellular carcinoma: a meta-analysis

Hepatitis B Virus X Protein Mutants Exhibit Distinct Biological Activities in Hepatoma Huh7 Cells

Hepatitis B Virus X Protein Promotes P3 Transcript Expression of the Insulin‐like Growth Factor 2 Gene Via Inducing Hypomethylation of P3 Promoter in Hepatocellular Carcinoma

[Mechanism and Clinical Significance of HBx-mediated Inhibition of CYP2E1 Expression in the Human HepG2 Hepatoma Cell Line].

HBx regulates transcription factor PAX8 stabilization to promote the progression of hepatocellular carcinoma